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Abstract
Critical to viral infection are the multiple interactions between viral proteins
and host-cell counterparts. The first such interaction is the recognition of
viral envelope proteins by surface receptors that normally fulfil other phys-
iological roles, a hijacking mechanism perfected over the course of evolu-
tion. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
etiological agent of coronavirus disease 2019 (COVID-19), has successfully
adopted this strategy using its spike glycoprotein to dock on the membrane-
boundmetalloprotease angiotensin-converting enzyme 2 (ACE2).The crys-
tal structures of several SARS-CoV-2 proteins alone or in complex with their
receptors or other ligands were recently solved at an unprecedented pace.
This accomplishment is partly due to the increasing availability of data on
other coronaviruses and ACE2 over the past 18 years. Likewise, other key in-
tervening actors and mechanisms of viral infection were elucidated with the
aid of biophysical approaches. An understanding of the various structurally
important motifs of the interacting partners provides key mechanistic infor-
mation for the development of structure-based designer drugs able to inhibit
various steps of the infective cycle, including neutralizing antibodies, small
organic drugs, and vaccines. This review analyzes current progress and the
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1. INTRODUCTION
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute res-
piratory syndrome (SARS) coronavirus (CoV) 2 (SARS-CoV-2) constitutes a very serious public
health problem worldwide. Some CoVs are enzootic, i.e., restricted to animals, whereas others
have crossed the species barrier to become zoonotic diseases in humans. Thus, CoVs cause respi-
ratory, neurological, enteric, and hepatic diseases of varying degrees of severity in animals ranging
from birds to Beluga whales.CoVs belong to the subfamilyCoronavirinae in theCoronaviridae fam-
ily and can be subdivided into four genera: α, β, γ, and δ (28, 65). CoVs pack inside their envelope
between 26 and 32 kilobases of single-stranded positive-sense RNA. In general, CoVs have a high
frequency of recombination and high mutation rates, which may have allowed them to adapt to a
wide variety of ecological niches and hosts (61). The mechanism of cross-species spillover remains
poorly understood.
Seven human CoVs (HCoVs) have been identified to date. HCoV-OC43,HCoV-293,HCoV-
NL63, and HKU1-CoV generally cause mild, self-limiting respiratory diseases, mainly forms of
the common cold; other forms of the common cold are caused by rhinoviruses and the parain-
fluenza virus, among others. A second category of HCoVs are SARS-CoV and Middle East respi-
ratory syndrome (MERS)-CoV, the etiological agents of SARS and MERS, the causative agents
of the epidemics in 2003 and 2012, respectively, which, like the recently emerged SARS-CoV-2
(the agent of COVID-19), are highly pathogenic viruses. The full genome of SARS-CoV-2 shares
79.5% sequence identity with SARS-CoV and 50% with MERS-CoV and is 96% identical to the
genomic sequence of the Chinese bat CoV, BatCoV RaTG13 (171).
The reader is referred to comprehensive reviews on the biological and evolutionary aspects
(73), epidemiology (122), clinical aspects (31, 106), physicochemical properties (109), and struc-



















































































Cell tropism and the host range of CoVs are largely determined by structural modifications oc-
curring in the spike (S) proteins during evolution, involving variations in their amino acid residue
exposure, stability, and resulting dynamics.Only a few weeks after the outbreak of COVID-19 and
the discovery of SARS-CoV-2, there was an explosion of high-resolution X-ray crystallographic
and cryo-electron microscopy (cryo-EM) studies on the structure of the viral S proteins alone
or in complex with the virus cell-surface receptor, the metalloprotease angiotensin-converting
enzyme 2 (ACE2), and of other proteases key to the viral cell cycle. This would have been an im-
possible task to achieve in such a short time were it not for the pioneering crystallography work
begun almost two decades ago on the structure of the related SARS-CoV and MERS-CoV (69,
124). This is a brilliant example of how the field of biophysics has been positioned at the forefront
of research to contribute swiftly in a crisis of global proportions.
2. OVERALL STRUCTURE OF THE SARS-COV-2 VIRION
The cryo-EM images of the SARS-CoV-2 virion isolated from the supernatant of infected VeroE6
cells show roughly spherical bodies with a diameter of 91 ± 11 nm (50), i.e., very similar to other
members of the Coronaviridae (92, 93, 152). The early transmission EM images obtained by June
Dalziel Almeida of “previously uncharacterized human respiratory viruses” in the late 1960s were
the first observations of the spikes at the surface of the virion that gave rise to the hitherto un-
known genus of CoVs (1). CoVs possess four main structural proteins, which are assembled at the
endoplasmic reticulum–Golgi intermediate compartment (ERGIC) of the host cell (59): nucle-
ocapsid (N), S, envelope (E), and membrane (M) proteins (Figure 1). In addition, their genome
codes for 16 nonstructural proteins (nsp1–nsp16) involved in key aspects of the CoV replication
cycle, such as papain-like protease (PLPRO), 3-chymotrypsin-like protease (3CLPRO) or main pro-
tease (MPRO), RNA-dependent RNA polymerase (RdRp), helicase, and exonuclease. PLPRO is a
domain of nsp3. Eight accessory proteins named by their open reading frame (orf ) succession
(orf3a, orf6, orf7a, orf7b, orf8, orf9b, orf9c, and orf10) are present in this type of virus (21).
a b
Figure 1
(a) Schematic diagram of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) showing the
membrane protein, the envelope protein, and the spike protein. Model created by Alissa Eckert and Dan
Higgins at the Centers for Disease Control and Prevention. (b) Pseudocolored negatively stained electron
micrograph of SARS-CoV-2. The spikes of the virus are clearly visible surrounding the perimeter of the
envelope sphere. Both images are public domain illustrations obtained through the Public Health Image
Library and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.










































































The N protein is a homodimer that resides together with the genomic RNA in the ribonucle-
oprotein (RNP) core inside the envelope. Early EM observations showed that the RNP complex
released from HCoV-229E is a helix 14–16 nm in diameter and up to 320 nm in length (78). The
RNP–genome complex is packed inside a capsid of variable size, from an 84 nm mean diameter
for murine CoV (M-CoV, MHV) (94) to 120 nm in the case of the bottlenose dolphin BdCoV
HKU22 virus, a γ-CoV, the largest observed to date for RNA viruses (66, 122, 150).TheN protein
chaperones and provides protection to the RNA genome, particularly during its replication cycle
and transit along the ERGIC during the viral cycle in the host cell.
The M protein is a major component of the viral envelope. It is an integral membrane glyco-
protein whose main functions are to adapt a region of the membrane for virus assembly and help
define the shape of the viral envelope. It can adopt two conformations, elongated and compact.
Elongated M proteins rigidize the membrane and produce the aggregation of S proteins in clus-
ters; compact M proteins are associated with a more flexible membrane with low spike density
(94). In the case of SARS-CoV, once the virion is internalized, the interaction of the M protein
with the S protein is required for retention of S protein in the ERGIC (89).
The E protein is a substoichiometric (relative to the other structural proteins) component
of CoVs whose precise function is still unknown except that it has ion channel properties, for
which reason it is classified as a viroporin (131). It is currently assumed that the E protein con-
tributes to the later stages of the virion cycle in the infected cell—the assembly and the bud-
ding processes (94). It is a small (76- to 109-amino-acid) integral membrane protein with a short
hydrophilic amino-terminus, a relatively long hydrophobic transmembrane domain, and a long
carboxy-terminus (160). Mutagenesis of its helical hydrophobic transmembrane domain alters
virus replication, which is restored upon reestablishing the native α-helical structure. Restored
E protein is more sensitive to treatment with the ion channel inhibitor hexamethylene amiloride
(160). The E protein of MHV CoV-A59 localizes at the ERGIC membranes and subsequently at
the Golgi complex, but its role in virionmorphogenesis is not known.The E protein does not traf-
fic to the cell surface (136). It should be mentioned that the E protein is not the only ion channel
molecule in CoVs, as discussed in Section 7 of this review.
The S protein structure is analyzed in detail in the sections below.
3. THE MOLECULAR MACHINERY INVOLVED IN
VIRUS–RECEPTOR INTERACTIONS
3.1. First Step in Viral Infection: CoV Recognition by Cell-Surface Receptors
The appearance of ligand recognition in living organisms has occurred in various instances as
a consequence of coevolution between interacting partners. However, the crosstalk between the
CoV infective molecular machinery and eukaryotic cell-surface receptors may differ from this co-
evolutionary mechanism because the receptors, which are transmembrane proteases in the case of
CoVs, fulfill preexisting physiological roles in eukaryotic cells (e.g., blood pressure regulation via
cleavage of angiotensin II in the case of ACE2), which these viruses exploit to serve their own spe-
cific purpose through plastic adaptations.One reason why ACE2 is selected by the virus as a target
molecule is probably the ubiquitous distribution of the membrane-bound enzyme in many tissues,
particularly mucosal epithelia. The architecture of the mucosae lining, for instance, the intestinal
tract is designed to maximize surface expanse for nutrient absorption, offering the virus abundant
surface area for its landing on the apical membrane surface. Subsequently, the virions could diffuse
by randomly walking the membrane until they collide with their target receptors, in a typical re-













































































hypothesized that ancestral forms of CoVs may have lacked parts of the host-cell receptor recog-
nition machinery and thus relied on this two-dimensional diffusion mechanism to reach their
targets (see below). Epithelial cells lining the oral (33, 156), nasal (33, 98, 176), bronchoalveolar
(54, 147, 171), and enteric (36, 46, 62) mucosae cover an enormous area in mammalian organisms;
this combined area is dominated by the upper respiratory tract and pulmonary alveolar area, with
values of 118 ± 22 m2 and 91 ± 18 m2 in male and female humans, respectively (16), and the
enteric mucosa, with an even larger total surface of 260–300 m2 (35). In vitro, polarized epithe-
lial cell cultures show predominant ACE2 expression at the apical cell surface rather than at the
basolateral membranes; SARS-CoV uses the apical plasmalemma to infect epithelium (43). Simi-
larly, SARS-CoV-2 utilizes this target surface in humanmucosae (171). Thus, the initial molecular
recognition and binding steps are intimately linked to viral cellular tropism.
3.2. Cell-Surface Binding: The Viral S Glycoprotein
By the time of the first CoV epidemic, our understanding of the biology, biochemistry, and molec-
ular biology of CoVs was quite advanced; it is therefore not surprising that the pioneer X-ray
crystallographic studies of CoV addressed the surface S glycoprotein, the region of the virus that
plays the central role in binding to its receptor and infection at large. The S protein is a trimer
composed of three S1–S2 subunit heterodimers. With negative staining EM (68) (see Figure 1b)
or, more recently, cryo-EM (50, 163, 165), the S protein trimer ectodomain of CoVs appears as
a clover-shaped body approximately 25 ± 9 nm long, with a stalk formed by a trimer of S2 sub-
units and three heads of S1 subunits. In cryo-EM, the predominant form observed at the surface
of intact virions is the clover-shaped body, which corresponds to the prefusion conformers; a less
abundant, extended, thin morphology, attributable to the postfusion conformer, is also observed
(50). Coverage of the SARS-CoV-2 surface by S protein trimers is sparse: The density is approx-
imately 1 spike/500 nm2 (50).
Each S1 N-terminal region contains a receptor binding domain (RBD), the region recognized
by the counterpart surface of the ACE2 receptor. Figure 2a shows the prefusion structure of
the S1 protein, highlighting the two conformations of the RBD, down (closed) and up (open),
the latter corresponding to the binding-enabled conformer in only one of the S1 protomers. The
trimeric morphology is more readily apparent in end-on views, exemplified in Figure 2b,c, which
shows the cryo-EM electron density of the MERS-CoV.
Each trimer of the S glycoprotein of SARS-CoV-2 contains 66 N-linked glycosylation sites
in its glycan moiety, apparently involved in viral protein folding, stability, and tropism (145) and
shielding of the virus from the host defense mechanisms (7). The glycosylation sites are under
selective pressure and camouflage viral epitopes from being recognized and neutralized by host
antibodies. This immune evasion mechanism is also observed with the human immunodeficiency
virus (HIV) envelope glycoprotein (116).
3.3. The Host-Cell Membrane-Embedded Proteases and Their Interaction
with the S Protein
Over the course of its evolution, ACE2 has acquired the capacity to interact with quite a few host-
cell proteases that aid in the viral infection process, such as cathepsins L and B, trypsin, elastase,
furin,TMPRSS2, andTMPRSS4 (88). In addition to ACE2, the surface glycoprotein CD147, also
termed Basigin or EMMPRIN, has been purported to act as a receptor for SARS-CoV-2 (141).
CD147 is a member of the immunoglobulin superfamily. Interestingly, an antagonist of CD147,
peptide-9, inhibits the binding of SARS-CoV-2 to HEK293 cells (141).






























































































(a) Lateral view of the S glycoprotein trimer of SARS-CoV-2 in the closed (left, PDB ID 6vxx) and open
(right, PDB ID 6vyb) crystal forms. The three protomers are colored light cyan, gray, and light orange.
Buried in the closed state, the RBD (orange) from one of the protomers (light orange) swings up in the open,
binding-ready conformation (169). (b) Low-resolution cryo-EM electron density of the overall structure of
the dissociated S1 trimer of MERS-CoV. (c) Ribbon rendering of the MERS-CoV S1 trimer, including the
three NTDs, RBDs, SD1s, and SD2s of each protomer in the trimer (165). Figure reproduced from open
access articles distributed under the terms of the Creative Commons CC BY license. Abbreviations: EM,
electron microscopy; MERS-CoV, Middle East respiratory syndrome coronavirus; NTD, N-terminal
domain; PDB, Protein Data Bank; RBD, receptor binding domain; S, spike; SARS-CoV-2, severe acute
respiratory syndrome coronavirus 2; SD, subdomain.
The recent X-ray and cryo-EM structures of the SARS-CoV-2 S protein, as well as recently
discovered details of the RBD that resides in the S1 subunit and of its membrane-bound cognate
receptor, the enzyme ACE2 in complex with the S1 subunit, have delivered invaluable information
on the mechanism of SARS-CoV-2 recognition and binding to the host-cell surface (63, 110, 137,
152, 159). As stated in Section 1, this tour de force could be accomplished in an unprecedentedly
short time partly because of the groundwork that preceded it and the new capabilities of cryo-
EM techniques. In this section, we analyze the new data and draw comparisons with the known
structures and mechanisms of related viruses.
Historically, of the two binding partners, ACE2’s structure was the first to be solved at the
atomic scale. ACE2 is the enzyme that catalyzes the hydrolysis of angiotensin II into angiotensin











































































activity. In contrast to its closest homolog, the somatic ACE peptidyl dipeptidase enzyme ACE,
ACE2 displays carboxypeptidase activity.The catalytic domains of the two enzymes are 42% iden-
tical (134). ACE2 purified from Vero E6 cells was found to be the receptor for SARS-CoV, and
a soluble form of the enzyme was shown to inhibit the binding of the S1 subunit of the virus to
ACE2-expressing cells (72). ACE2 is a glycoprotein, and its glycans at two glycosylated sites, N90
and N322, contribute in an opposite manner to the virus–ACE2 binding interaction, as demon-
strated by a recent in silicomolecular dynamics study (86).N90 partly covers the binding interface,
interfering with the docking of S1 onto ACE2, whereas N322 interacts tightly with the RBD of
S1 in its bound state, binding to a conserved region previously identified as a cryptic epitope for
a neutralizing antibody (172).
The similar architectural design of the CoV spike proteins is indicative of the similar
mechanistic strategies developed to infect cells. CoVs have chosen membrane-bound proteases
to accomplish this task. Thus, human H229E-CoV, transmissible gastroenteritis virus, porcine
epidemic diarrhea virus, and feline infectious peritonitis virus are recognized by another zinc met-
alloprotease, aminopeptidase N [APN, also known as cluster of differentiation 13 (CD13)] (70).
MHV, a β-CoV, employs mouse cell adhesion carcinoembryonic antigen-related cell adhesion
molecule 1 (mCEACAM1) to bind its S1 N-term domain (60). The host-cell receptor molecule
hijacked by MERS-CoV is the enzyme dipeptidyl-peptidase 4 (DPP4), also known as CD26 (65,
71).
Studies of ACE2 were preceded by X-ray determination of the structure of the human testicu-
lar ACE in complex with the inhibitor lisinopril {N2 -[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-
proline} at 2.0 Å resolution (91). On the basis of this structure, a homology model was produced
suggesting the complementarity of the viral binding domain of ACE2 and the SARS-CoV S1
protein (102). One year later, Carfi and collaborators (124) studied the X-ray structure of the pro-
teolytically stable core of SARS-CoV. The crystallographic data of this β-CoV constituted one
of the first descriptions at the atomic level. This was followed in 2005 by a key X-ray diffraction
study at 2.9 Å of the SARS-CoV S glycoprotein in complex with human ACE2 by Harrison and
coworkers (69). The combined crystallographic data disclosed two domains in ACE2: the core
region (124) and the RBD, comprised of the residues between 306 and 527, within which a loop
formed by residues 424–494 corresponded to the receptor binding motif (RBM) in SARS-CoV.
In addition to the three proteases acting as receptors for CoVs, the evolutionarily versatile
MERS-CoV was also found to infect host cells upon binding to a completely different type of
host-cell receptor, i.e., the oligosaccharide moieties of surface glycoproteins; the binding to α2,3-
sialoside sites is highly specific but of low affinity (71). Cryo-EM disclosed the structure of the
MERS S protein region involved in interactions with the receptor carbohydrates: It is a conserved
groove (Figure 3), different from the RBD, located at the peripheral region of the S1 subunit
trimer (97).
HCoV-NL63, a respiratory virus, is the only human α-CoV that uses ACE2 as its receptor
(SARS-CoV and SARS-CoV-2 belong to the β).Wu and coworkers (153) determined the structure
of the RBDof theHCoV-NL63 complexed with humanACE2 using cryo-EM.TheHCoV-NL63
RBD showed two layers of β-sheets (a beta-sandwich) and three discontinuous RBMs that contact
ACE2. HCoV-NL63 and SARS-CoV have no structural homology in RBD cores or RBMs, yet
the two viruses recognize common ACE2 regions, leading Wu and coworkers to postulate the
occurrence of a “virus-binding hotspot” on ACE2 (153, p. 19970). Interestingly, among α- (also
called group 1) CoVs, RBD cores are conserved, but RBMs are variable, providing a plausible ex-
planation for how these viruses can recognize different receptors (153). Along these lines, a recent
phylogenetic study postulates that SARS-CoV-2 could potentially recognize ACE2 isoforms from
various animal species (139).















































































Surface rendering representation of theMERS-CoV S glycoprotein showing the location of the crevice where
interaction with its receptor’s neuraminic acid (Neu5Ac) occurs. (a) Local resolution map, calculated using
cryoSPARC, as indicated in the color-coded scale. (b) Detail of the region (lilac) surrounding the crevice. The
receptor’s neuraminic acid molecule is shown in gray-red stick rendering. Figure adapted from Reference 97,
which is made available via the PMC Open Access Subset for unrestricted research re-use and secondary
analysis in any form or by any means with acknowledgement of the original source for the duration of
the World Health Organization declaration of COVID-19 as a global pandemic. Abbreviations: COVID-19,
coronavirus disease 2019; MERS-CoV, Middle East respiratory syndrome coronavirus; S, spike protein.
Another human β-CoV,HKU1-CoV, in contrast to the related pathogenic β-CoVs SARS-CoV
and MERS-CoV, causes mild, predominantly respiratory disease. Its structure in the prefusion
conformation was solved at 4.0 Å resolution using single-particle cryo-EM (55). At that time, the
receptor for HKU1-CoV was not known, but antibodies against the C-terminal domain (CTD)
blocked infection, suggesting that this region of the virus was responsible for attaching to the tar-
get cell. The cryo-EM structural data of the S1 protein–ACE2 complex revealed that only one
S1 RBD of the trimeric S glycoprotein binds ACE2, adopting an open, protruding up confor-
mation much like that of other CoVs (see Figure 2), which enables it to recognize the ACE2
site while keeping the fusion S2 domain distant from this target. The prefusion conformer of the
porcine epidemic diarrhea (PEDV) α-CoV S protein, solved using cryo-EM at 3.1 Å, has provided
more information on the heterogeneity of conformational states that the S protein undergoes to
make the RBD accessible for host-cell binding to its receptor, APN (151).
The structure of the SARS-CoV-2 S protein homotrimer was initially solved in its prefusion
stage by Wrapp et al. (152) and Walls et al. (137) using cryo-EM. The former study found that
the structure of the SARS-CoV-2 S protein is quite similar to that of the human β-CoV HKU1-
CoV, obtained using cryo-EM (55). The cryo-EM study by Walls et al. identified the occurrence
of two conformers of the SARS-CoV-2 S protein—open and closed—as has been observed in
other CoVs. The closed conformer corresponds to the prefusion structure proper, since the three
RBDs of the S protein homotrimer lie flat in a down position, buried at the interface between the
three protomers, whereas the open conformer, which is the predominant form, shows one RBD
protruding in an up state, ready for binding to ACE2.
Furin is a membrane-bound enzyme of the subtilisin-like proprotein convertase family that
cleaves sections of recently synthesized inactive proteins to render them active. Detaching
some redundant amino acid motifs (four Pro-Arg-Arg-Ala sequences) in the SARS-CoV-2 S











































































described the presence of a furin proteolytic site at the S1–S2 boundary—a feature absent in other
CoVs like SARS-CoV and apparently unique to SARS-CoV-2 in the CoV clade, as is shown by
sequence analyses (18). Furin cleavage overcomes the apparently default state (mostly in the down
conformation) of the SARS-CoV-2 spike RBD, which is inefficient for host-cell binding. Another
cryo-EM study of the SARS-CoV-2 S protein confirmed the furin cleavage site between the S1
and S2 subunits (146). The cryo-EM studies also revealed the solvent accessibility of the S1/S2
region rendered available by the furin cleavage interactions with cell-surface receptors (146, 152).
Other studies indicate the coexistence of pre- and postfusion homotrimeric conformers on the
surface of mature SARS-CoV-2 virions (7) with a statistically predominant prefusion form, which
occurs in three varieties: fully closed (approximately 41%) trimers, trimers with one RBD up
(45%), and trimers with two RBDs in the open up conformation (13%) (50).
3.4. Exact Stoichiometry of Virus S1 Protein Receptor Is Still Uncertain
The ratio between virus spikes and host-cell membrane-bound receptor sites varies among CoVs
because of the nature of the cell-surface receptors. For example, one of the MERS-CoV S1
domains of its spike protein trimer binds a homodimeric CD26 (DPP4) molecule, its host-cell
membrane-bound receptor, enabling the two other S1 domains of the trimer to bind two addi-
tional CD26 receptors and giving rise to a complex supramolecular structure consisting of arrays
of receptors recruited by S proteins (Figure 4a). In contrast, the consensus view is that the SARS-
CoV-2 RBD binds one extracellular peptidase domain of ACE2 in a one-to-one molar ratio (38,
69, 118, 146) (Figure 4b). However, one ACE2 receptor can apparently recruit two S trimers of
SARS-CoV-2 (159). In solution, a spike protein can bind up to three ACE2 ectodomains in a pH-
dependent manner (172), suggesting a potential binding capacity like that of MERS-CoV. This
study also indicates that the S1 domain evades potentially neutralizing antibodies by conforma-
tionally masking a cryptic epitope that can be disrupted by pH changes.
A cryo-EM study of the S1 protein trimer–ACE2 complex of SARS-CoV (118) described a













Models of MERS-CoV and SARS-CoV S trimers bound to their receptors. The models were built by
superimposition of the S trimer structures with the RBD–receptor complex structures through the RBD
domains. (a) The MERS-CoV S trimer can crosslink the homodimeric CD26 receptor during binding,
enabling the binding of the two additional S1 subdomains of the trimer, whereas (b) the SARS-CoV S trimer
can bind one monomeric ACE2 receptor in a 1:1 complex. Figure adapted from Reference 165, held under
Creative Commons license. Abbreviations: ACE2, angiotensin-converting enzyme 2; CD26, cluster of
differentiation 26; MERS-CoV, Middle East respiratory syndrome coronavirus; RBD, receptor binding
domain; S, spike; SARS-CoV, severe acute respiratory syndrome coronavirus.










































































cluster together and adopt a rosette-like structure (118). The authors of this study hypothesized
that the opening of the SARS-CoV S1 subunit upon binding to the ACE2 receptor may promote
the release of the S1–ACE2 complex and S1 monomers from the prefusion spike, triggering the
conformational transition from prefusion to postfusion conformers.
3.5. The Receptor Binding Domain of the S Glycoprotein S1 Subunit
During the course of evolution, CoVs have needed to develop a mechanism for temporarily mask-
ing the RBD until the opportunity arises to engage in receptor recognition. This masking is pre-
sumably necessary to prevent the S protein from fusing with nontarget membranes and to escape
neutralization by the host humoral immune response (133). The S1 subunit of the S glycoprotein
possesses an N-terminal domain (NTD) and a CTD. Both domains can engage as a receptor-
binding partner of the membrane-bound host-cell receptors: SARS-CoV and MERS-CoV em-
ploy the S1 CTD (69, 75), whereas MHV utilizes its S1 NTD to bind to its receptor (126). Initial
attempts to identify the RBD in a CoV resulted in the isolation of a 193-amino-acid peptide frag-
ment (residues 318–510) of the SARS-CoV S protein that bound efficiently to ACE2 and blocked
S protein–mediated infection (149). The RBD is located at the tip of the S1 subunit head and
therefore lies distant from the zinc-chelating catalytic site of ACE2 when bound to the host-cell
enzyme (Figure 2).
The crystal structure of SARS-CoV in complex with human ACE2 disclosed the fine struc-
ture of the RBD, which consists of a core and a subregion termed the RBM. This critical region
contacts the complementary surface of ACE2 (67, 69). The core domain consists of five-stranded
antiparallel β-sheets. The RBD possesses a subtly concave surface in the case of SARS-CoV and
SARS-CoV-2 (Figures 5 and 6), and a flat surface in the case of MERS-CoV. The contact area
of the MERS-CoV S RBD in complex with its receptor molecule, the protease DPP4, is sur-
prisingly dominated by hydrophilic amino acid residues (75), unlike those of the SARS-CoV and
SARS-CoV-2 RBDs, which include hydrophobic amino acids (see Figure 5).
X-ray diffraction of the CTD of SARS-CoV-2 in complex with human ACE2 at 2.5 Å resolu-
tion showed that the CTD of the S1 protein, consisting of amino acids 318–510 and containing
the RBD, establishes more atomic interactions than the RBD of SARS-CoV does, an observation
that correlates with biochemical data showing that SARS-CoV-2 has a higher affinity for receptor
binding (143), although, as analyzed below, this is still a matter of debate. During the binding
process, 20 residues in ACEs interact with 17 residues of the SARS-CoV-2 RBD (63). The area
subtended at the contact interface is approximately 1,700 Å2 (20, 63).
A recent molecular modeling exercise revealed the similarity between the geometric and
physicochemical properties of the viral RBD–ACE2 interfaces of SARS-CoV and SARS-CoV-2
and those of antibody–antigen contacts stabilized by electrostatic interactions, suggesting that
the two otherwise dissimilar systems have followed similar evolutionary maturation pathways (4).
A cryo-EM study of the full-length human ACE2 apoenzyme, alone or in complex with the
RBD of the SARS-CoV-2 S protein, at 2.9-Å (3.5 Å at the RBD) resolution suggests that the RBDs
of two trimers of S1 can simultaneously bind to a dimer of ACE2 molecules (159). The study was
conducted in the presence of a neutral amino acid transporter, B°AT1, which grants stability to
the crystal structure.
The affinity of the receptor for the binding partner, the S1 protein, has been assessed using
a variety of approaches, with varying results. Numerical calculations derived from molecular
modeling studies concluded that the SARS-CoV RBD has a higher affinity than that of SARS-
CoV-2 (13); other studies indicate similar affinities (17, 146), and in some cases, SARS-CoV-2


























































































The S1 protein RBM–ACE2 interface. Human ACE2 (PDB ID 6M0J; green ribbon) is shown at the top, and
the RBD of the S protein S1 subunit is shown at the bottom; the RBD of the SARS-CoV (PDB ID 2AJF)
appears in red, and the SARS-CoV-2 homologous region of the S1 protein (PDB ID 6M0J) appears in
magenta, with its RBM in blue. The key intervening residues at the interface are shown as sticks, labeled with
the same color as the corresponding molecules. The SARS-CoV-2 RBD–ACE2 interface possesses three
more salt bridges (K31, E35, and K353 from ACE2 and Q493 and G496 from the RBD) connecting the two
molecules than the interface between SARS-CoV and the enzyme (63). Figure adapted from Reference 73.
Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
Abbreviations: ACE2, angiotensin-converting enzyme 2; PDB, Protein Data Bank; RBD, receptor binding









Comparison of the RBDs of SARS-CoV (white; PDB ID 2AJF) and SARS-CoV-2 (with the nomenclature of
the original figure, 2019-nCoV). Residues that vary in the latter are shown in red. The binding site for
landing the RBD onto ACE2 is better appreciated in the 180° rotated figure on the right (outlined with a
black dashed line) (152). This makes the binding interface of the SARS-CoV-2 larger than that of the
SARS-CoV (111). Furthermore, from the excess surface at the ridge of the SARS-CoV-2 RBD in its complex
with ACE2 (63), one can infer that its RBD offers a better contact than that of SARS-CoV. These structural
differences may constitute the basis of the differences in affinity of the two viruses for the common host-cell
receptor, ACE2. Abbreviations: ACE2, angiotensin-converting enzyme 2; EM, electron microscopy; PDB,
Protein Data Bank; RBD, receptor binding domain; SARS-CoV, severe acute respiratory virus coronavirus.










































































(152). Biophysical studies combining single-molecule force spectroscopy and steered molecular
dynamics also support the higher strength of the interactions of SARS-CoV-2–ACE2 than the
counterpart interactions of SARS-CoV with its receptor (8).
The higher affinity of SARS-CoV-2 for ACE2 is attributed to the more compact conformation
of the binding ridge in its RBD and the presence of several residues in the SARS-CoV-2 RBD that
stabilize two binding hot spots at the RBD–ACE2 interface (63, 111) (Figure 6). Lan et al. (63)
found that RaTG13, a bat coronavirus closely related to SARS-CoV-2, can also use the human
ACE2 as its receptor, providing new clues to the possible animal-to-human transmission of SARS-
CoV-2. Similar cryo-EM work by McLellan and coworkers (152) at 3.5 Å resolution found that
one of themajor differences between the RBDs of the two viruses is the position in their respective
down conformations, which is closer to the central cavity of the trimer in SARS-CoV-2. In the
same study, the kinetics of the RBD–ACE2 interaction, quantified with surface plasmon resonance,
yielded an equilibrium dissociation constant, Kd, of approximately 5 nM for the SARS-CoV-2
RBD, indicating that the ectodomain of this virus exhibits up to 10–20 times more affinity for
ACE2 than does that of SARS-CoV.
Although the affinity of the RBD of SARS-CoV-2 for human ACE2 is higher than that of
SARS-CoV, the affinities of the entire S proteins have been reported to be similar, or even lower,
for SARS-CoV-2 (110). According to Shang et al. (110), affinities depend on the average configu-
ration of the S protein; in SARS-CoV-2, the RBD is mostly in the down, less accessible conformer
(not binding enabled), thus resulting in lower affinity. One biomedically important implication is
that the hidden RBD of SARS-CoV-2 can evade immune surveillance and therefore provide in-
sufficient immune response to COVID-19 compared to SARS.
Mainly because of its role in host-cell receptor recognition, the S1 protein subunit has domi-
nated attention as a target for drug discovery and pharmacological intervention. Two recent pre-
liminarymolecular dynamics studies shifted the focus to the S2 subunit protein of the heterodimer
(protomer of the S trimer). In the first study, two regions in the S2 subunit of the dimer and the
hinge connecting the S1 and S2 subunits were identified (12). In the second study, the S2 subunit
was found to exhibit much less variability and flexibility than the RBD domain in the S1 sub-
unit (48). In addition, the latter study identified a highly conserved cavity in the SARS-CoV-2
S glycoprotein between two protomers of the trimer. The cavity can bind small macrolide-type
and chitosan molecules that could destabilize the trimer, making these two small ligands potential
inhibitory drugs.
When the host-cell lipid response was characterized using high-performance liquid chro-
matography and mass spectrometry–based lipidomics, glycerophospholipids and fatty acids were
found to be significantly altered upon infection with the human coronavirus HCoV-229E; this
was particularly true of the metabolism of the fatty acids linoleic acid and arachidonic acid (158).
Recently, the SARS-CoV-2 S proteinwas produced in a secreted trimeric formusing a baculovirus-
Hi5 insect system. The cryo-EM structure at 2.85 Å resolution of the trimeric S protein (which
occurs in the closed conformation in 70% of the cases) disclosed the presence of a tightly bound
molecule of linoleic acid, an essential fatty acid, in a pocket located in each of the three RBDs (132).
The hallmarks of fatty acid–binding pockets in proteins are a hydrophobic bent-tube cylindrical
domain that accommodates the hydrocarbon tail and a hydrophilic domain that interacts with the
acidic head-group region of the fatty acid. In the case of SARS-CoV-2, the hydrophobic domain
in the RBD is mainly populated by Phe residues, and an Arg residue provides the anchor for the
fatty acid head (Figure 7). SARS-CoV and MERS-CoV viruses harbor the same pocket, but in
their case, linoleic acid stabilizes a locked conformation of the S protein that interacts less than
the native conformer with its receptor in vitro. The linoleic acid pocket in SARS-CoV-2 may have
important biomedical connotations. Linoleic acid supplementation appears to act synergistically












































































Surface rendering of a linoleic acid molecule (orange stick-and-ball) tightly bound to the SARS-CoV-2 RBD
pocket. Blue and red correspond to positive and negative surface charges, respectively. Figure adapted from
Reference 132, distributed under a Creative Commons Attribution Noncommercial License 4.0 (CC
BY-NC). Abbreviations: RBD, receptor binding domain; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2.
4. MEMBRANE FUSION: THE S2 FUSOGENIC SUBUNIT AND THE
HOST-CELL PROTEASES THAT ENABLE ITS ENGAGEMENT
The intimately coupled processes of binding to and fusion with the host-cell membrane have been
described as conserved mechanisms that may have followed a separate evolutionary path in dif-
ferent CoVs (67). According to this view, ancestral CoVs would have had a primordial spike with
S2 domains only; the lack of an S1 made them functionally inefficient, relying on random diffu-
sion across the host membrane, and membrane fusion would have thus randomly occurred in a
receptor-independent manner. Gene capture would have subsequently allowed the S protein to
acquire a galectin-like S1 NTD, an important evolutionary step that enhanced CoV efficiency in
infecting cells. In a final evolutionary step, the S1 protein would have acquired a CTD through
gene duplication of the S1 NTD (67). Comprehensive accounts of the membrane fusion mecha-
nism can be found in recent reviews (127, 133).
Although CoVs can utilize different membrane-bound receptors and fusion mechanisms to
enter cells, a generalized model of envelope membrane fusion with the host-cell plasmalemma
can be considered. The model, developed during the past 15 years, involves (a) a molecular inter-
action between the virion S protein and a cell-surface enzyme acting as receptor, with or without
a coreceptor; (b) two concerted enzymic cuts of the S glycoprotein catalyzed by two different
proteases, separating S1 from the S2 subunit; and (c) structural rearrangements of S2 mediat-
ing the transition from the prefusion to the postfusion conformation (for a detailed review, see
133).
In the prefusion stage, three S1 receptor binding subunits of the S glycoprotein rest flat at the
tip of the spike above the fusion-mediating S2 subunit, clamped down by a segment adjacent to
the fusion peptide, thus preventing the S2 fusion core from undergoing the conformational tran-
sitions required for fusion (see Figure 2). Upon binding to ACE2, the viral S protein is cleaved by
host-cell proteases at the S1–S2 interface. This constitutes the priming step, accompanied by a se-
ries of conformational transitions that enable the fusion-competent state of the S protein (88); the
creation of an elongated trimeric hairpin structure formed by two heptad repeats, 1 and 2 (7); and










































































the release of the spike fusion peptide (the functional fusogenic element of the S protein), a pro-
cess that is well characterized for SARS-CoV (56). This first step can be accomplished by several
host-cell proteases, such as TMPRSS2 and cathepsins B and L, which, depending on their avail-
ability at the plasmalemma, determine viral tropism (127). TMPRSS2 is a transmembrane type
2 serine protease resident in the host-cell plasmalemma; it is hijacked by Ebola virus, CoVs, and
filoviruses to infect the organism (173). TMPRSS2 is required by the three human pathogenic
CoVs MERS-CoV (105, 112), SARS-CoV (82), and SARS-CoV-2 (38). When it is present,
TMPRSS2 makes cells highly susceptible to SARS-CoV-2 infection (83); in fact, TMPRSS2 has
been suggested to play the role of coreceptor for SARS-CoV-2 at the plasmalemma. The drug
camostat blocks TMPRSS2, impeding NL63-HCoV, SARS-CoV (49), and MERS-CoV entry
into cells (112). Camostat also acts as an inhibitor of Ebola virus (173). Cathepsins B and L are
endosomal-resident cysteine proteases that can also produce the enzymatic dissociation of S1 and
S2 in the priming step. Furthermore, furin has been demonstrated to enzymatically act at the
S1/S2 site in the case of SARS-CoV-2 (152, 153).
A subsequent cleavage at a second site, S2′, located upstream of the fusion peptide in S2, has
been reported to activate MERS-CoV (88) but not SARS-CoV or SARS-CoV-2. Membrane fu-
sion can occur via an early plasmalemma or via the endosomal membrane pathway, depending on
the availability of the proteases at either location. SARS-CoV-2 can use both pathways (38). In the
SARS-CoV-2 S protein, the redundant furin-cut motifs need to be cleaved to enable the activation
(priming) of S1 and virion entry into the host cell (110). This results in the extended conformation
of S2 that enables subsequent insertion of the fusion peptide into the host membrane. The free
energy to overcome the energetic barrier for membrane fusion is provided by the refolding of
the fusion protein from the primer prefusion conformer to the fusion-competent postfusion con-
former (34). The crystal structure of the two conformers has been characterized for SARS-CoV-2
(7, 50) (Figure 8).
The spontaneous host-cell receptor–independent dissociation of the three S1 subunits from
the S2 subunit has recently been postulated (7). This hypothesis posits that both pre- and postfu-
sion conformations of the S protein coexist in the mature virion in a varying ratio; the extensive
decoration of the S2 subunit with N-linked glycans led to the suggestion that these glycans fulfill
a protective role for the postfusion conformer, should it be exposed on the surface of the mature
virion, by, e.g., inducing non-neutralizing antibody responses to evade host immune reaction. EM
images of naked S2 postfusion conformers on the intact virion surface seem to support this con-
tention (25); the extended thin structures reminiscent of the postfusion S2 conformer constitute
a minority of observed structures (50). Further research is required to ascertain the mechanism of
virion fusion with the host-cell membranes.
5. WHAT DO THE ENDOGENOUS VIRAL PROTEASES DO?
Once the virion has penetrated the host cell, it needs to replicate its genome and produce its own
proteins: structural proteins, nsps and accessory proteins. A large proportion of the CoV genome
corresponds to the orfs 1a and 1ab, which are translated into the two viral replicase polyproteins
pp1a and pp1ab. In both H229E-CoV (175) and SARS-CoV, these two large precursor polypro-
teins are in turn cleaved into 16 nsps by the chymotrypsin-like protease and the virus-encoded
chymotrypsin-like 3C-like proteinase (3CLPRO), also termed main protease (MPRO). The nsps can
thereafter engage in the production of subgenomic RNAs that encode, in turn, no less than the
four structural proteins of SARS-CoV-2 (19). MPRO is thus essential for the genomic and subge-















































































Prefusion and postfusion S trimer structures determined on the surface of intact SARS-CoV-2 virions by
cryo-EM using subtomogram averaging. The structures are shown as transparent grey isosurfaces fitted with
structures of the closed, metastable prefusion SARS-CoV-2 S trimer [PDB ID 6VXX, with one monomer
colored orange (C terminus)], with its RBD in cyan (left) and the postfusion SARS-CoV S trimer (PDB ID
6XRA) with one subunit in orange (right). Image courtesy of Drs. Zulong Ke and John Briggs, Laboratory of
Molecular Biology, Medical Research Council, Cambridge, UK. Abbreviations: EM, electron microscopy;
PDB, Protein Data Bank; RBD, receptor binding domain; S, spike; SARS-CoV, severe acute respiratory
syndrome coronavirus.
Rao and coworkers (157) determined the crystal structures of an MPRO mutant from SARS-
CoV and the infectious bronchitis virus. The MPRO protease appears to be a challenging target
for small-drug inhibition (6). The recently determined structures of SARS-CoV-2 MPRO (Protein
Data Bank ID 6LU7), in complex either with an α-ketoamide inhibitor (166) and two structure-
based design additional inhibitors, 11a and 11b (19), or in complex with the inhibitor N3 at a
resolution of 2.1 Å (47), pave the way for the development of inhibitors of the endogenous viral
proteases with improved properties in comparison to current first- and second-line antiretroviral
drugs in HIV therapy (114).
In SARS-CoV-2, another key endogenous viral protease is PLPRO, whose atomic structure
is still not known. Based on available crystallographic data of the PLPRO from SARS-CoV and
MERS-CoV, a recent homology modeling study found that the PLPRO of SARS-CoV-2 is 97%
homologous to that of a bat CoV, 80% homologous to SARS-CoV, and only 29% homologous to
MERS-CoV (120).
6. STRUCTURAL KNOWLEDGE OPENS NEW AVENUES FOR DRUG,
VACCINE, AND ANTIBODY DEVELOPMENTS
The structural information that has been accumulated about CoV structure has revealed potential
epitopes on the virions, prompting new ideas for small drugs (see 3), vaccines (41, 72, 118, 121,
124), and neutralizing antibodies (44, 77, 154, 165) on a much more solid basis.










































































The differences in amino acid residues present in the RBD responsible for attachment to
the cell host ACE2 (Figure 3) may account for the different affinities of SARS-CoV and SARS-
CoV-2. As suggested by Veesler and coworkers (138), an interesting evolutionarily conserved
feature of CoVs appears to be their fine-tuned balance between masking of the RBM, to limit
neutralization by the humoral host immune response, and their necessary exposure, to enable
receptor recognition and infection of host cells.
A wide palette of antibodies were already available against SARS-CoV andMERS-CoV; amea-
sure of how far the field has advanced is provided by the variety of neutralizing antibodies that
specifically address the RBD: monoclonal antibodies (mAbs), antigen-binding fragments (Fabs),
single-chain variable region fragments (scFv), or single-domain antibodies (nanobodies) (for re-
views, see 44, 174). Antibodies raised against SARS-CoV pseudovirions (i.e., an artificial con-
struction of, e.g., a lentivirion carrying the SARS-CoV S1 protein) do not necessarily recognize
epitopes in SARS-CoV-2, as is the case with T62 polyclonal antibodies (95), but other antibodies
raised against pseudoviruses do cross-react with both viruses and offer therapeutic potential as
neutralizing antibodies (77).
The crystal structure of the SARS-CoV S protein RBD at 2.2 Å resolution, its structure in
complex with the human neutralizing antibody 80R at 2.3 Å resolution (40), and a similar structure
at 2.3 Å resolution of the SARS-CoV RBD with the monoclonal antibody m396 (101) led to
the conclusion that antibodies and ACE2 compete for the same highly immunogenic surfaces of
the virus spike; in fact, the antibodies act as competitive inhibitor ligands of ACE2. The crystal
structure of a neutralizing antibody isolated from a convalescent patient suffering from SARS,
termedCR3022 (129), in complex with the RBD of the SARS-CoV-2 S protein at 3.1 Å resolution,
led to the identification of a conserved epitope in the new virus, distal from the ACE2 binding site
(164). Molecular modeling further suggested that the binding epitope is a cryptic site that can
only be accessed by CR3022 when at least two of the three RBDs on the S protein homotrimer
are in the up conformation and slightly rotated (164). The buried epitope covers an area of 917 Å2,
and the binding to the antibody is driven mostly by hydrophobic interactions. That this antibody
generated against SARS-CoV in a SARS patient can recognize the RBD of SARS-CoV-2 can be
accounted for by the high degree of amino acid conservation in the epitope (86%) (164), higher
than the homology in the complete S1 protein (∼77%) (171).
As this review is being written, only six months after the outbreak of the COVID-19 pandemic,
new biotechnological possibilities of vaccine development have appeared. One emerging strategy
is the use of viral messenger RNA (mRNA) to elicit the immune response against the spike pro-
tein. One such vaccine, known as mRNA-1273, has already gone beyond animal tests and passed
phase 1 clinical trials (42); this vaccine is currently positioned at stages conventionally achieved
after many more months in the making (see https://corona.kpwashingtonresearch.org/). An-
other recent effort is the development of a preclinical SARS-CoV-2 pilot-scale vaccine candidate
using as starting material strains of the virus isolated from bronchoalveolar fluid samples from 11
hospitalized patients in China and various European countries. Interestingly, the SARS-CoV-2
strains employed are widely scattered from a phylogenetic point of view. The new experimentally
inactivated vaccine candidate, PiCoVacc, induced SARS-CoV-2-specific neutralizing antibodies
in animal models, providing protection against a SARS-CoV-2 challenge in macaques (25). A
third example is Biovacc-19, a candidate vaccine currently in the preclinical stage after passing
acute toxicity testing, targeted to nonhuman-like epitopes on the SARS-CoV-2 S protein (119).
Sørensen et al. (119) searched all known human proteins looking for sequence homologies with
the S protein and, because the S protein exhibits 78.4% similarity with human-like epitopes,
chose only nonhuman-like epitopes in their vaccine strategy to avoid autoimmune responses











































































immunoinformatics approach based on immune genomics has screened regions of the S1 spike
protein and the MPRO protease of SARS-CoV-2 with the aim of identifying epitopes for devel-
oping vaccine candidates (96). The structural data are already providing useful hints at vaccine-
and structure-guided immunogen design and raising the possibility that SARS-CoV-2 undergoes
antigenic drift, as influenza viruses do (7).
The first monoclonal antibodies recently isolated from a convalescent COVID-19 patient ex-
hibit neutralizing ability, blocking the binding of the SARS-CoV-2 S protein RBD to ACE2 (154).
Another work has described the production of a human monoclonal antibody against both SARS-
CoV-2 and SARS-CoV (140). The antibody, 47D11, was shown in vitro to bind to HEK-293T
cells expressing green fluorescent protein–tagged spike proteins of the two viruses and to inhibit
VeroE6 cell infection with either of the two CoVs. Wang et al. (140) suggest the possibility that
the antibody destabilizes the prefusion conformation of the spike protein via receptor functional
mimicry, as was previously described for the anti-SARS-CoV antibody (138). Another area of vac-
cine biotechnology that is acquiring momentum is structure-guided design of antigens having
better immunogenic properties than those of the metastable native S protein. Along these lines,
prefusion-stabilized versions of the S protein offer interesting possibilities (39). Prefusion stabi-
lization creates immunogens that are more stable than their wild-type counterparts and increases
the recombinant expression of viral fusion glycoproteins, most likely by precluding triggering or
misfolding due to the protein’s tendency to adopt the more stable postfusion structure. Testing
combinations of substitutions led to the identification of an S protein variant with six beneficial
proline substitutions that award approximately 10-fold higher expression and capacity to with-
stand heat stress, freeze–thaw cycles, and storage at room temperature (39). A similar approach
has been followed by Briggs and coworkers (155) andVesleer and coworkers (84), producingmuta-
tions in the S protein leading to thermostable, disulfide-bonded S-protein trimers that are trapped
in the closed, prefusion state.
In summary, structural biology studies have great potential in the biotechnology of vaccine
development; however, the time-constrained road ahead is not easy, and complications lie along
the way, as attested to by the increasing number of immunotypes and immune responses being
found in SARS-CoV-2-infected patients (81). More than 800 epitopes were recently disclosed in
the SARS-CoV-2 proteome using machine learning approaches (113).
In addition to surface proteins, 16 nsps intervene in the life cycle of CoVs; some are conserved,
like the RNA-dependent RNA polymerase RdRp; the main protease MPRO; and nsp13, a helicase
that can unwind both DNA and RNA, while others are not. A chemoproteomic analysis involving
cloning, tagging, and expression of 26 out of the 29 proteins of SARS-CoV-2 in a human cell
expression system disclosed an extensive, hierarchically ordered connectivity network between
viral nsps and host-cell proteins, with >330 node contacts and three main hubs that disrupt the
normal functions of the cell (30).
Cryo-EM and X-ray crystallography have revealed important structural–functional correla-
tions in these diverse groups of nsps. An example is nsp3, a large multidomain protein, part of
which corresponds to the enzyme ADP-ribose phosphatase or macrodomain (MacroD).This pro-
tein apparently interferes with the host immune response due to its ability to detach the ADP-
ribose moiety from ADP-ribosylated proteins. The apoform of nsp3 and the complexes of the
enzyme with various ligands have been solved at 1.07–2.01 Å resolution by X-ray diffraction tech-
niques (87). Given the importance of the macrodomains in viral load,Michalska et al. (87) suggest
the possible development of antiviral drugs against nsp3, pointing to the challenge of discriminat-
ing between the viral and human forms of the enzyme (24).
The nsp that is receiving the most attention is nsp12, the polymerase RdRp. The task of this
protein is nothing less than to transcribe the viral genes into the adapter mRNA molecules and










































































replicate the approximately 32,000-nucleotide-long RNA genome. A peculiarity of viral RdRp
is the error-prone character of its genome replication capacity. This apparent fault enables the
viruses to rapidly undergo mutations that, e.g., improve their infectivity or adaptation to new
hosts. When incorporated into a nascent RNA chain, the adenosine nucleotide analog chain ter-
minator remdesivir acts as a broad-spectrum inhibitor of RdRp.The drugwas originally developed
for the treatment of the Ebola viral disease and was subsequently applied to MERS and respira-
tory syncytial virosis (128). Xu and coworkers (161) obtained the structure of the apoform of the
SARS-CoV-2 RdRp at 2.8 Å resolution and in complex with a 50-base template-primer RNA-
remdesivir at 2.5 Å resolution using cryo-EM. The study of RdRp in a conformation mimicking
its active form was also tackled with cryo-EM by the Cramer group at the Max Planck Institute
for Biophysical Chemistry in Göttingen (37).Detailed features of RNA processing by RdRp could
be inferred from the complex of two turns of RNA, with the active site cleft of RdRp holding the
first turn and two copies of nsp8 bound to opposite sides of the cleft. These two studies provide
new insights into the mechanisms utilized by antivirals such as remdesivir and into the design of
better inhibitors of the viral RNA polymerase. The Rao group in Shanghai studied SARS-CoV-2
RdRp in complex with the other two intervening nsps, nsp7 and nsp8, using cryo-EM at 2.9 Å
resolution (26). Other very similar cryo-EMwork from the same group studied the pre- and post-
translocated RdRp in complex with cofactors nsp7 and nsp8, showing that the three molecules
in the complex undergo significant structural rearrangements when interacting with RNA and
positioning the template and primer (142). These studies facilitated in vitro assays of inhibitory
drugs like remdesivir, leading to the conclusion that this drug causes RNA chain termination in
vitro (29). Remdesivir has received considerable attention and has been tested against COVID-19
in clinical trials; preliminary results suggest that it may reduce the time to recovery in seriously ill
patients (for a recent review, see 3). Likewise, the nsp15 endonuclease NendoU of SARS-CoV-2,
which is approximately 90% homologous to that of SARS-CoV, was thought to be engaged in
viral replication in a direct manner, but more recent X-ray crystallographic studies at 1.9 Å reso-
lution suggest that it does so indirectly, by interfering with the host’s immune response and thus
augmenting the virulence of SARS-CoV-2 (53). Another SARS-CoV-2 nsp with high similarity
to the nsps of SARS-CoV is nsp9, a protein requiring dimerization to engage in viral replication,
virulence, and genomic RNA replication. An X-ray diffraction study at approximately 2 Å resolu-
tion identified a potential binding site for peptide inhibitors. At the time of writing of this article,
the Protein Data Bank Europe lists more than 230 structures and 180 ligands of SARS-CoV-2 in
its COVID-19 Data Portal (https://www.ebi.ac.uk/pdbe/covid-19).
7. ION CHANNELS IN SARS-COV-2
SARS-CoV infection requires the expression of several endogenous viral ion channel–forming
proteins, also termed viroporins (74), as is also the case in other CoVs. Viroporins display an over-
all low degree of homology with ion channel proteins of prokaryotic or eukaryotic origin; the
transmembrane regions of some of the viroporins, however, appear to have a higher degree of
homology with the corresponding regions of ion channels from higher organisms, suggesting a
common ancestry (23). In SARS-CoV, in between the genes coding for the S protein and the viral
envelope genes there is a conserved orf region (168). One of the genes expressed in this region
corresponds to orf4a, also known as the E protein, a 76–109-amino-acid protein with the capacity
to form homopentameric transmembrane ion channels and regulate virus release. SARS-CoV en-
codes two additional ion channel proteins: orf8a and orf3a (9). Orf8a is a Cys-rich 29-amino-acid
single-passage transmembrane peptide that forms cation-selective ion channels with a conduc-











































































third ion channel in SARS-CoV, orf3a, has three transmembrane domains in each protomer, ar-
ranged in a homotetrameric complex in vitro (76), with the characteristics of a cation channel with
modest selectivity for Ca2+ and K+ over Na+. Suppression of orf3a expression abrogates SARS-
CoV release (76), and its deletion reduces viral titer and morbidity in animal models, suggesting
that orf3a-targeted drugs could find therapeutic applications in SARS and COVID-19 (51).
Given its recent discovery, our knowledge of these proteins in SARS-CoV-2 is very scant. Nu-
clear magnetic resonance (NMR) data of the SARS-CoV E protein transmembrane region (125)
was used to map surface epitopes in the SARS-CoV-2 homologous protein (130). An NMR study
showed that the E protein, when it is reconstituted in phospholipid bilayers with a composition
resembling that of the ERGIC, adopts pentameric structure (80). A preliminary cryo-EM study
of SARS-CoV-2 orf3a reconstituted in lipid nanodisks has recently appeared (51), showing dimers
with three transmembrane segments each and tetramers structurally resembling those reported
by Lu and coworkers (76) for the SARS-CoV homologous protein. The topic of ion channels in
SARS-CoV-2 and other CoVs is still underdeveloped, with ample territory remaining to explore.
8. STRUCTURE–FUNCTION CORRELATIONS
Deciphering the fine structure of individual viral components is of great importance in under-
standing the mechanisms of pathogenic infection and for dissecting the molecular actors of the
various steps (Figure 9). Knowledge of the virus domain(s) that binds to the cognate membrane
receptor (ACE2) and engages in the recognition step is essential not only to comprehend the
pathophysiology but also to design suitable strategies to inhibit these key initial steps of viral in-
fection. The recently obtained atomic structure of the S protein trimeric complex and its two
subunits S1 and S2 provided sufficient detail to delineate the interactions of this complex with
its host-cell docking receptor, ACE2 (63, 110, 137, 152, 159), and calculate its affinity (17, 143,
146).Our knowledge of the ensuing enzyme-mediated conformational transitions of the S protein,
which promote fusion of the virus with the host-cell plasmalemma, also benefited from recently
acquired information on the enzyme cleavage sites unveiled in the structural studies (18, 110,
137). The practical implications of these structure–function correlations are readily apparent: For
example, activating the expression of CD74 p41, whose canonical role is antigen presentation,
was recently found to inhibit SARS-CoV-2 entry by blocking cathepsin-mediated processing and
endosomal entry of the virus (5).
Once inside the cell, the viral envelope is uncoated, and the viral RNA genome is translated,
initially producing the pp1a and pp1ab polyproteins. The synergistic combination of the viral
proteases PLPRO and MPRO undertakes the proteolytic cleavage of the two polyproteins to pro-
duce nsp1, nsp2, and itself (in the case of PLPRO) and the rest of the 16 mature nsps (in the case of
MPRO). Some of these nsps are further involved in the organization of the replication–transcription
complex (RTC). The RTC is a membrane-associated RNA-protein assembly responsible for the
replication of the entire RNA genome and production of subgenomic mRNAs coding for the
SARS-CoV-2 structural proteins (19). Morphologically, the RTC, also called the replication or-
ganelle (RO) (115), consists of double-membrane vesicles (DMVs) approximately 250–300 nm in
diameter. The most important component of the RTC is the RdRp (nsp12) (26, 37, 161), which
requires the aid of nsp7 and nsp8. A recent cryo-EM tomography study of cells infected with
SARS-CoV-2 revealed the existence of a pore traversing the two adjacent lipid bilayers of the
DMVs, formed by six copies of nsp3, essential for viral replication (148). The viral structural
proteins, together with the additional accessory orf proteins of SARS-CoV-2, are synthesized,
folded—including the important trimerization of the S protein—and post-translationally modi-
fied in the ER and the ERGIC (Figure 9), a clear manifestation of the control exerted by the virus





































































































































The life cycle of SARS-CoV-2. Shown are the different steps of the virus inside a mammalian cell, from initial binding to its cognate
receptor, the membrane-bound ACE2 enzyme (step 1), to its final exit from the cell (step 8). A recent work disclosed that coronaviruses
use lysosomes instead of the exocytic biosynthetic secretory pathway (27). Abbreviations: ACE2, angiotensin-converting enzyme 2;
CMs, convoluted membranes; DMVs, double-membrane vesicles (a central hub for the synthesis of viral RNA); ER, endoplasmic
reticulum; ERGIC, endoplasmic reticulum–Golgi intermediate compartment (where most of the post-translational modifications take
place); RdRp (nsp12), RNA-dependent RNA polymerase; RO, replication organelle (the modified ERGIC subserving the replication of
the viral RNA; see Reference 148); RTC, replication–transcription complex; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2; sDMS, small open invaginated double-membrane spherules; TMPRSS2, transmembrane type 2 serine protease.
on the host-cell biosynthetic machinery. Additional post-translational modifications also occur in
the ERGIC and the Golgi complex, where proteins initially disulfide-bonded or cotranslationally
N-glycosylated at conserved sites in the ER lumen (145) are further O-glycosylated at the Golgi
apparatus, thus providing another source of diversity to the repertoire of viral proteins. The orf
accessory proteins adjuvate in the assembly process in the ERGIC and in the transport of the
virions along the exocytic pathway.
Whereas the viral RdRp is error prone, the host-cell exocytic compartment has sophisticated
control mechanisms to ensure a homeostatic balance of protein synthesis, folding, conformational
stability, and degradation, generically known as proteostasis (57). The degradative arm of the pro-
teostatic mechanism is the ER-associated degradation (ERAD) pathway, a quality-control system
that avoids the clogging of the exocytic secretory pathway with excess or misfolded proteins (123).
The ERAD sorts misfolded proteins to the lysosome and vacuole or to the proteasome; some pro-
teins escape this control and are sorted at the Golgi complex. In CoV infection, ERAD-related
proteins intervene in a complex termed the EDEMosome, a morphologically modified ERGIC
membrane subcompartment consisting of DMVs, shared with the RTC (115). This pore enables
the nascent RNA to escape the replication complex in the RO (Figure 9). Having completed their
secretory pathway transit, mature virions are released by exocytosis, or more likely via lysosomes











































































9. OUTLOOK AND PROSPECTS
The mechanism of virus infection and the pathophysiology of the virus-infected cells and tissues
are areas of virus research requiring further exploration and may benefit from cutting-edge bio-
physical approaches. Two of the hottest areas of current research efforts are undoubtedly vaccine
and neutralizing antibody developments, and the S protein is a major target in both instances
because of the role it plays in receptor recognition and initiation of infection. Structure-guided
substitutions that increase protein yield or stability of engineered prefusion synthetic S protein
(39) and engineering of human ACE2 dimers to act as a soluble decoy receptor with affinities com-
parable to monoclonal antibodies (10) will be two areas of intense research in the months to come.
Small design decoy molecules are also potential tools to neutralize the virus. This is only part of
the story: Of the new crystal structures deposited in the cryo-EM repository in 2020, roughly half
correspond to proteins other than the S protein.
Organoids constitute a model system that is increasingly being applied to biomedical research.
These are 3D ex vivo self-organized cultures derived from pluripotent stem cells, including human
induced pluripotent stem cells (iPSCs) (15, 52, 85). In the specific case of SARS and COVID-19,
3D lung organoids are a step ahead of the classical 2D polarized epithelial cultures, since they
can differentiate the stem cell–derived mesodermal and endodermal cells into branching airway
and alveolar structures, mimicking more closely the pulmonary anatomy (100). Organoids dif-
ferentiated into 3D mini-brains with several of the cytoarchitectural properties of the brain are
already available (64). They have been employed to study Zika (22), SARS (100), and more re-
cently COVID-19 (170). The latter application was recently implemented using 9-week-old brain
organoids grown from iPSCs, showing the successful infection of neurons by SARS-CoV-2 and
the upregulation of cell division and metabolic pathways in the infected cells (117).One can imag-
ine exploiting the potentiality of organoids as high-throughput screening (HTS) platforms for,
e.g., pharmacological small-drug, antibody, and vaccine screening. In the case of brain organoids,
it is even possible to produce brain region–specific organoids using mini-bioreactors (103, 104).
Which are the most biologically relevant and urgent questions to be addressed in this area of
research using structural biology and biophysical approaches? The recent advances in molecular
biology of CoVs, yielding high-resolution atomic coordinates of the virus machinery’s engage-
ment with host-cell receptor molecules, has required 3D crystals for X-ray diffraction and single
molecules in 2D arrangements for cryo-EM techniques. However, these powerful approaches are
still incapable of interrogating an entire living cell during the infection process or observing the
virus in action during its replicative cycle. Traditional transmission EM has remained the gold
standard technique for conventional morphological studies of virus from a cell biology perspec-
tive, with lateral resolutions on the order of 2–5 nm and a penetration depth of approximately
500 nm (14, 167), but much like X-ray diffraction or cryo-EM, the biological specimens almost
invariably need to be fixed, either chemically or physically. A mesoscale method with 3D capabili-
ties, cryo-soft X-ray tomography of vitrified specimens, has a penetration depth of approximately
10 μm and circumvents chemical fixation (99). The technique has already been applied in cell bi-
ology in combination with single-molecule (135) or structured illumination (58) superresolution
microscopies.
To delve into the realm of cell biology in action, we need to take a step back from the atomic
into the nanometer scale, where we currently have the tools to image objects in live cells beyond
the diffraction limit of light, i.e., the optical nanoscopies. A wide palette of techniques in optical
superresolution microscopy is currently available to visualize viruses using conventional optics
and visible light: the stochastic superresolution methods; the so-called single-molecule localiza-
tion microscopies (SMLM), such as stochastic optical reconstruction microscopy, photoactivated










































































localization microscopy, or DNA points accumulation for imaging in nanoscale topography
(DNA-PAINT); and the deterministic superresolution methods, such as stimulated emission de-
pletion (STED), reversible saturable or switchable optical fluorescence transitions, or ground-
state depletion microscopies, to cite the most common variants (for reviews, see 79, 108).
Minflux (2), a new form of nanoscopy, combines elements of the SMLM approach (individ-
ual on–off fluorophore switching) and the deterministic nanoscopies (an excitation beam with an
intensity minimum, mimicking the doughnut in STED), affording a spatial resolution one order
of magnitude better than the above classical superresolution techniques; this technique has been
recently extended to the localization of molecules in 3D (32). This puts Minflux in an excellent
position to study the localization of virus particles and their topographical relationship to sub-
cellular organelles occurring at distances previously only accessible to Förster resonance energy
transfer, the primary molecular ruler in fluorescence imaging to date. Ingenuity will be required
to optimize the current nanoscopy instrumentation to operate under biosafety conditions ade-
quate for handling intact, infective virions during imaging experiments with living cells. Correla-
tive optical nanoscopy/cryo-EM offers interesting possibilities by combining mesoscale informa-
tion on viral dynamics captured with superresolution optical microscopy at different stages of the
replicative cycle with cryo-tomography of thin samples obtained with serial cryo-focused ion beam
milling. The latter would provide fine details of the viral subcellular localization and pathogenic
alterations.
By no means have biophysical methods using harsher wavelengths, such as those of electrons,
been exhausted. New techniques have become available, for instance, using genetically encoded
protein tags to capture gold nanoparticles, enabling visualization of individual protein molecules
in a cellular environment (45). The combination of improved electron optics stability in the EM
proper, cold-field emission guns optimized for narrow electron energy spread (or monochroma-
tors) to reduce chromatic aberration, next-generation direct electron detectors with improved
quantum efficiency and speed, automatized data collection with subpixel accuracy, and increased
computational power blended with sophisticated image processing software has produced a silent
revolution in cryo-EM, making true visualization of atomic coordinates in biological macro-
molecules a reality.The 1.25 Å structure of the apoferritin molecule solved by the group of Holger
Stark at theMax Planck Institute for Biophysical Chemistry in Göttingen,Germany (162) and the
1.7 Å resolution cryo-EM reconstruction of the β3 GABAA receptor, an homopentameric con-
struct of this transmembrane ligand-gated ion channel, by Sjors Scheres’ group at the Laboratory
of Molecular Biology of theMedical Research Council in Cambridge in the United Kingdom (90)
attest to the advances in cryo-EM resulting ultimately from a better signal-to-noise ratio (107).
Progress is likely to be accomplished on other fronts, such as improvements in the preservation of
biological specimens. In the specific applications covered in this review, these advances will enable
the capture of different conformational states of the virus and the use of the microscope as a tool
for the HTS of potential antiviral drugs.
10. CONCLUDING REMARKS
Although the first known case of HIV-1 infection occurred in 1959 in a patient in what is now
the Democratic Republic of Congo, the virus was only identified, isolated, and characterized at
the Pasteur Institute in Paris in 1983 and at the National Institutes of Health in Bethesda, Mary-
land, in 1984. SARS-CoV-2, the etiological agent of COVID-19, was identified inWuhan, China,
and its sequence posted online on January 10, 2020, only a couple of weeks after the outbreak
of the “cluster of pneumonia of unknown origin,” the nosological entity that we now know as











































































tackling a biomedical problem of unprecedented proportions. Biophysics was probably the first
scientific discipline to produce solid data in attempts to understand the etiological agent and the
pathogenesis of the disease and in the search for its biomedical remediation. There are still many
open paths that could contribute to these endeavors and thus help prevent future pandemics.
SUMMARY POINTS
1. Biophysics and structural biology were among the first disciplines in science to react to
the new pandemic outbreak.
2. The crystal structures of the new SARS-CoV-2, alone or in complex with its host-cell
receptor or other ligands, were obtained at an unprecedented pace, partly thanks to the
structural biology groundwork in the preceding two decades.
3. The novel findings have shone new light on important mechanistic aspects of viral infec-
tion. Probably the best-studied facet is the recognition of the viral S proteins by host-cell
surface receptors.
4. In the case of SARS-CoV-2, the etiological agent of COVID-19, new information about
the atomic structure of its S glycoprotein bound to the membrane-bound metallopro-
tease ACE2 has greatly advanced our understanding of the initial step in the infective
process.
5. New structurally and functionally important motifs have been disclosed in both struc-
tural and nonstructural proteins of the new virus.
6. Key mechanistic information conducive to the development of structure-based in-
hibitory design drugs, neutralizing antibodies, and vaccines has been produced within
a few weeks.
7. As a direct result, various prophylactic and therapeutic tools are being developed at an
unparalleled pace.
FUTURE ISSUES
1. Structural research addressed at unraveling structure–function correlations will continue
to help us gain a better understanding of the still unresolved and biomedically important
mechanisms operating in viral infection.
2. The recent developments in single-particle cryo-EM, having achieved visualization of
individual atoms in intact proteins, will facilitate the identification of specific sites and
motifs in the viral structure amenable to inhibition by design drugs.
3. Likewise, the most recent developments in optical microscopy (nanoscopy) may open
new avenues to explore the virus cycle in living cells.
4. The combined use of structural and electrophysiological biophysical techniques may
prove useful in tackling the study of viral ion channel proteins (viroporins) in SARS-
CoV-2 for interventional purposes.
5. Structure-based design approaches will increasingly be applied to the development and
production of more stable immunogenic SARS-CoV-2 fragments and decoy molecules
to neutralize the virus.
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36. Hikmet F, Méar L, Edvinsson Å, Micke P, Uhlén M, Lindskog C. 2020. The protein expression profile
of ACE2 in human tissues.Mol. Syst. Biol. 16:e9610
37. Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D, Cramer P. 2020. Structure of replicating
SARS-CoV-2 polymerase.Nature 584:154–56
38. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, et al. 2020. SARS-CoV-2 cell entry
depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.Cell 181:271–
80.e8
39. Hsieh C-L, Goldsmith JA, Schaub JM, DiVenere AM, Kuo H-C, et al. 2020. Structure-based design of
prefusion-stabilized SARS-CoV-2 spikes. Science 369:1501–5
40. Hwang WC, Lin Y, Santelli E, Sui J, Jaroszewski L, et al. 2006. Structural basis of neutralization by a
human anti-severe acute respiratory syndrome spike protein antibody, 80R. J. Biol. Chem. 281:34610–16
41. Imai Y, Kuba K, Rao S, Huan Y, Guo F, et al. 2005. Angiotensin-converting enzyme 2 protects from
severe acute lung failure.Nature 436:112–16










































































42. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, et al. 2020. An mRNA vaccine
against SARS-CoV-2—preliminary report.N. Engl. J. Med. 383:1920–31
43. Jia HP, Look DC, Shi L, Hickey M, Pewe L, et al. 2005. ACE2 receptor expression and severe acute
respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J.Virol.
79:14614–21
44. Jiang S, Hillyer C, Du L. 2020. Neutralizing antibodies against SARS-CoV-2 and other human coron-
aviruses. Trends Immunol. 41:355–59
45. Jiang Z, Jin X, Li Y, Liu S, Liu X-M, et al. 2020. Genetically encoded tags for direct synthesis of EM-
visible gold nanoparticles in cells.Nat. Methods 17:937–46
46. Jin X, Lian JS, Hu JH, Gao J, Zheng L, et al. 2020. Epidemiological, clinical and virological characteris-
tics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut
69:1002–9
47. Jin Z, Du X, Xu Y, Deng Y, Liu M, et al. 2020. Structure of M(pro) from SARS-CoV-2 and discovery
of its inhibitors.Nature 582:289–93
48. Kalathiya U, Padariya M, Mayordomo M, Lisowska M, Nicholson J, et al. 2020. Highly conserved ho-
motrimer cavity formed by the SARS-CoV-2 spike glycoprotein: a novel binding site.J.Clin.Med.9:1473
49. KawaseM,Shirato K, van derHoek L,Taguchi F,Matsuyama S. 2012. Simultaneous treatment of human
bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory
syndrome coronavirus entry. J. Virol. 86:6537–45
50. Ke Z, Oton J, Qu K, Cortese M, Zila V, et al. 2020. Structures and distributions of SARS-CoV-2 spike
proteins on intact virions.Nature 588:498–502
51. Kern DM, Sorum B, Hoel CM, Sridharan S, Remis JP, et al. 2020. Cryo-EM structure of the SARS-
CoV-2 3a ion channel in lipid nanodiscs. bioRxiv 156554. https://doi.org/10.1101/2020.06.17.
156554
52. Kim J,Koo B-K,Knoblich JA. 2020.Human organoids: model systems for human biology andmedicine.
Nat. Rev. Mol. Cell Biol. 21:571–84
53. Kim Y, Jedrzejczak R, Maltseva NI, Wilamowski M, Endres M, et al. 2020. Crystal structure of Nsp15
endoribonuclease NendoU from SARS-CoV-2. Protein Sci. 29:1596–605
54. Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, et al. 2020. Type 2 inflammation modu-
lates ACE2 and TMPRSS2 in airway epithelial cells. J. Allergy Clin. Immunol. 146:80–88.e8
55. Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, et al. 2016. Pre-fusion structure of a
human coronavirus spike protein.Nature 531:118–21
56. Kirchdoerfer RN,Wang N, Pallesen J, Wrapp D, Turner HL, et al. 2018. Stabilized coronavirus spikes
are resistant to conformational changes induced by receptor recognition or proteolysis. Sci. Rep. 8:15701
57. Klaips CL, Jayaraj GG, Hartl FU. 2018. Pathways of cellular proteostasis in aging and disease. J. Cell
Biol. 217:51–63
58. Kounatidis I, Stanifer ML, Phillips MA, Paul-Gilloteaux P, Heiligenstein X, et al. 2020. 3D correlative
cryo-structured illumination fluorescence and soft X-ray microscopy elucidates reovirus intracellular
release pathway. Cell 182:515–30.e17
59. Krijnse-Locker J, Ericsson M, Rottier PJ, Griffiths G. 1994. Characterization of the budding compart-
ment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only
one vesicular transport step. J. Cell Biol. 124:55–70
60. Kubo H, Yamada YK, Taguchi F. 1994. Localization of neutralizing epitopes and the receptor-binding
site within the amino-terminal 330 amino acids of the murine coronavirus spike protein. J. Virol.
68:5403–10
61. Lai MM, Cavanagh D. 1997. The molecular biology of coronaviruses. Adv. Virus Res. 48:1–100
62. Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, et al. 2020. SARS-CoV-2 productively
infects human gut enterocytes. Science 369:50–54
63. Lan J, Ge J, Yu J, Shan S, Zhou H, et al. 2020. Structure of the SARS-CoV-2 spike receptor-binding
domain bound to the ACE2 receptor.Nature 581:215–20
64. Lee CT, Bendriem RM,Wu WW, Shen RF. 2017. 3D brain organoids derived from pluripotent stem












































































65. Letko M, Miazgowicz K, McMinn R, Seifert SN, Sola I, et al. 2018. Adaptive evolution of MERS-CoV
to species variation in DPP4. Cell Rep. 24:1730–37
66. Li F. 2013. Receptor recognition and cross-species infections of SARS coronavirus.Antiv. Res. 100:246–
54
67. Li F. 2016. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3:237–61
68. Li F, Berardi M, Li W, Farzan M, Dormitzer PR, Harrison SC. 2006. Conformational states of the
severe acute respiratory syndrome coronavirus spike protein ectodomain. J. Virol. 80:6794–800
69. Li F,LiW,FarzanM,Harrison SC.2005. Structure of SARS coronavirus spike receptor-binding domain
complexed with receptor. Science 309:1864–68
70. LiW,Hulswit RJG,Kenney SP,Widjaja I, Jung K, et al. 2018. Broad receptor engagement of an emerg-
ing global coronavirus may potentiate its diverse cross-species transmissibility. 115:E5135–43
71. Li W, Hulswit RJG, Widjaja I, Raj VS, McBride R, et al. 2017. Identification of sialic acid-binding
function for the Middle East respiratory syndrome coronavirus spike glycoprotein. PNAS 114:E8508–
17
72. Li W,Moore MJ, Vasilieva N, Sui J, Wong SK, et al. 2003. Angiotensin-converting enzyme 2 is a func-
tional receptor for the SARS coronavirus.Nature 426:450–54
73. Li X, Giorgi EE, Marichannegowda MH, Foley B, Xiao C, et al. 2020. Emergence of SARS-CoV-2
through recombination and strong purifying selection. Sci. Adv. 6:eabb9153
74. Liao Y,Tam JP, Liu DX. 2006.Viroporin activity of SARS-CoV E protein.Adv. Exp.Med. Biol. 581:199–
202
75. Lu G, Hu Y,Wang Q, Qi J, Gao F, et al. 2013. Molecular basis of binding between novel human coro-
navirus MERS-CoV and its receptor CD26.Nature 500:227–31
76. Lu W, Zheng BJ, Xu K, Schwarz W, Du L, et al. 2006. Severe acute respiratory syndrome-associated
coronavirus 3a protein forms an ion channel and modulates virus release. PNAS 103:12540–45
77. Lv Z, Deng Y-Q, Ye Q, Cao L, Sun C-Y, et al. 2020. Structural basis for neutralization of SARS-CoV-2
and SARS-CoV by a potent therapeutic antibody. Science 369:1505–9
78. Macneughton MR, Davies HA. 1978. Ribonucleoprotein-like structures from coronavirus particles.
J. Gen. Virol. 39:545–49
79. Mahecic D, Testa I, Griffie J, Manley S. 2019. Strategies for increasing the throughput of super-
resolution microscopies. Curr. Opin. Chem. Biol. 51:84–91
80. Mandala VS,McKayMJ, Shcherbakov AA,Dregni AJ, Kolokouris A,HongM. 2020. Structure and drug
binding of the SARS-CoV-2 envelope protein in phospholipid bilayers.Nat. Struct. Mol. Biol. 27:1202–8
81. Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, et al. 2020. Deep immune profiling of
COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369:eabc8511
82. Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. 2010. Efficient activation of the
severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.
J. Virol. 84:12658–64
83. Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, et al. 2020. Enhanced isolation of SARS-CoV-2
by TMPRSS2-expressing cells. PNAS 117:7001–3
84. McCallum M,Walls A, Bowen JE, Corti D, Veesler D. 2020. Structure-guided covalent stabilization of
coronavirus spike glycoprotein trimers in the closed conformation.Nat. Struct. Mol. Biol. 27:942–49
85. McCauley HA, Wells JM. 2017. Pluripotent stem cell-derived organoids: using principles of develop-
mental biology to grow human tissues in a dish.Development 144:958–62
86. Mehdipour AR,HummerG. 2020.Dual nature of human ACE2 glycosylation in binding to SARS-CoV-
2 spike. bioRxiv 193680. https://doi.org/10.1101/2020.07.09.193680
87. Michalska K, Kim Y, Jedrzejczak R,Maltseva NI, Stols L, et al. 2020. Crystal structures of SARS-CoV-2
ADP-ribose phosphatase: from the apo form to ligand complexes. IUCrJ 7:814–24
88. Millet JK, Whittaker GR. 2015. Host cell proteases: critical determinants of coronavirus tropism and
pathogenesis. Virus Res. 202:120–34
89. Mortola E, Roy P. 2004. Efficient assembly and release of SARS coronavirus-like particles by a heterol-
ogous expression system. FEBS Lett. 576:174–78
90. Nakane T, Kotecha A, Sente A,McMullan G,Masiulis S, et al. 2020. Single-particle cryo-EM at atomic
resolution.Nature 587:152–56










































































91. Natesh R, Schwager SLU, Sturrock ED,Acharya KR. 2003.Crystal structure of the human angiotensin-
converting enzyme-lisinopril complex.Nature 421:551–54
92. Neuman BW, Adair BD, Yoshioka C, Quispe JD, Orca G, et al. 2006. Supramolecular architecture of
severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. J.Virol.80:7918–28
93. Neuman BW, Buchmeier MJ. 2016. Supramolecular architecture of the coronavirus particle. Adv. Virus
Res. 96:1–27
94. Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF, et al. 2011. A structural analysis of M protein
in coronavirus assembly and morphology. J. Struct. Biol. 174:11–22
95. Ou X, Liu Y, Lei X, Li P, Mi D, et al. 2020. Characterization of spike glycoprotein of SARS-CoV-2 on
virus entry and its immune cross-reactivity with SARS-CoV.Nat. Commun. 11:1620
96. Panda PK, Arul MN, Patel P, Verma SK, Luo W, et al. 2020. Structure-based drug designing and im-
munoinformatics approach for SARS-CoV-2. Sci. Adv. 6:eabb8097
97. Park YJ,Walls AC,Wang Z, Sauer MM,LiW, et al. 2019. Structures of MERS-CoV spike glycoprotein
in complex with sialoside attachment receptors.Nat. Struct. Mol. Biol. 26:1151–57
98. Patel AB, Verma A. 2020. Nasal ACE2 levels and COVID-19 in children. JAMA 323:2386–87
99. Pereiro E. 2019. Correlative cryo-soft X-ray tomography of cells. Biophys. Rev. 11:529–30
100. Porotto M, Ferren M, Chen YW, Siu Y, Makhsous N, et al. 2019. Authentic modeling of human respi-
ratory virus infection in human pluripotent stem cell-derived lung organoids.mBio 10(3):e00723-19
101. Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, et al. 2006. Structure of severe acute respiratory
syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J. Biol. Chem.
281:15829–36
102. Prabakaran P, Xiao X,Dimitrov DS. 2004. A model of the ACE2 structure and function as a SARS-CoV
receptor. Biochem. Biophys. Res. Commun. 314:235–41
103. Qian X, Jacob F, SongMM,Nguyen HN, Song H,Ming GL. 2018.Generation of human brain region-
specific organoids using a miniaturized spinning bioreactor.Nat. Protoc. 13:565–80
104. Qian X, Nguyen HN, Song MM, Hadiono C, Ogden SC, et al. 2016. Brain-region-specific organoids
using mini-bioreactors for modeling ZIKV exposure. Cell 165:1238–54
105. Qian Z, Dominguez SR,Holmes KV. 2013. Role of the spike glycoprotein of humanMiddle East respi-
ratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PLOS ONE 8:e76469
106. Richardson S, Hirsch JS, Narasimhan M, Crawford JM,McGinn T, et al. 2020. Presenting characteris-
tics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York
City area. JAMA 323:2052–59
107. Rosenthal PB, Henderson R. 2003. Optimal determination of particle orientation, absolute hand, and
contrast loss in single-particle electron cryomicroscopy. J. Mol. Biol. 333:721–45
108. Sahl SJ,Hell SW, Jakobs S. 2017.Fluorescence nanoscopy in cell biology.Nat.Rev.Mol.Cell Biol.18:685–
701
109. Scheller C, Krebs F, Minkner R, Astner I, Gil-Moles M, Wätzig H. 2020. Physicochemical properties
of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality
control. Electrophoresis 41:1137–51
110. Shang J, Wan Y, Luo C, Ye G, Geng Q, et al. 2020. Cell entry mechanisms of SARS-CoV-2. PNAS
117:11727–34
111. Shang J,YeG,Shi K,WanY,LuoC, et al. 2020. Structural basis of receptor recognition by SARS-CoV-2.
Nature 581:221–24
112. Shirato K, Kawase M, Matsuyama S. 2013. Middle East respiratory syndrome coronavirus infection
mediated by the transmembrane serine protease TMPRSS2. J. Virol. 87:12552–61
113. Shrock E, Fujimura E, Kula T, Timms RT, Lee I-H, et al. 2020. Viral epitope profiling of COVID-19
patients reveals cross-reactivity and correlates of severity. Science 370(6520):eabd4250
114. Sisay M. 2020. 3CL(pro) inhibitors as a potential therapeutic option for COVID-19: available evidence
and ongoing clinical trials. Pharmacol. Res. 156:104779
115. Snijder EJ, Limpens R, de Wilde AH, de Jong AWM, Zevenhoven-Dobbe JC, et al. 2020. A unifying












































































116. Sok D, Pauthner M, Briney B, Lee JH, Saye-Francisco KL, et al. 2016. A prominent site of antibody
vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging
glycans. Immunity 45:31–45
117. Song E, Zhang C, Israelow B, Lu P,Weizman O-E, et al. 2020. Neuroinvasive potential of SARS-CoV-
2 revealed in a human brain organoid model. bioRxiv 169946. https://doi.org/10.1101/2020.06.25.
169946
118. Song W, Gui M,Wang X, Xiang Y. 2018. Cryo-EM structure of the SARS coronavirus spike glycopro-
tein in complex with its host cell receptor ACE2. PLOS Pathog. 14:e1007236
119. Sørensen B, Susrud A,Dalgleish AG. 2020. Biovacc-19: a candidate vaccine for Covid-19 (SARS-CoV-2)
developed from analysis of its general method of action for infectivity. QRB Discov. 1:e6
120. Stoermer M. 2020. Homology models of the papain-like protease PLpro from coronavirus
2019-nCoV. chemRxiv. https://chemrxiv.org/articles/Homology_Models_of_the_Papain-Like_
Protease_PLpro_from_Coronavirus_2019-nCoV/11799705
121. Struck A-W, Axmann M, Pfefferle S, Drosten C,Meyer B. 2012. A hexapeptide of the receptor-binding
domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor
ACE2. Antivir. Res. 94:288–96
122. Su S, Wong G, Shi W, Liu J, Lai ACK, et al. 2016. Epidemiology, genetic recombination, and patho-
genesis of coronaviruses. Trends Microbiol. 24:490–502
123. Sun Z, Brodsky JL. 2019. Protein quality control in the secretory pathway. J. Cell Biol. 218:3171–87
124. Supekar VM, Bruckmann C, Ingallinella P, Bianchi E, Pessi A, Carfí A. 2004. Structure of a proteolyt-
ically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein. PNAS
101:17958–63
125. Surya W, Li Y, Torres J. 2018. Structural model of the SARS coronavirus E channel in LMPGmicelles.
Biochim. Biophys. Acta Biomembr. 1860:1309–17
126. Taguchi F, Hirai-Yuki A. 2012. Mouse hepatitis virus receptor as a determinant of the mouse suscepti-
bility to MHV infection. Front. Microbiol. 3:68
127. Tang T, Bidon M, Jaimes JA,Whittaker GR,Daniel S. 2020. Coronavirus membrane fusion mechanism
offers a potential target for antiviral development. Antivir. Res. 178:104792
128. Tchesnokov EP, Feng JY, Porter DP, Götte M. 2019. Mechanism of inhibition of Ebola virus RNA-
dependent RNA polymerase by remdesivir. Viruses 11:326
129. ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, et al. 2006. Human monoclonal
antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLOS Med.
3:e237
130. Tilocca B, Soggiu A, Sanguinetti M, Babini G, De Maio F, et al. 2020. Immunoinformatic analysis of
the SARS-CoV-2 envelope protein as a strategy to assess cross-protection against COVID-19.Microbes
Infect. 22:182–87
131. To J, Surya W, Torres J. 2016. Targeting the channel activity of viroporins. Adv. Protein Chem. Struct.
Biol. 104:307–55
132. Toelzer C, Gupta K, Yadav SKN, Borucu U, Davidson AD, et al. 2020. Free fatty acid binding pocket in
the locked structure of SARS-CoV-2 spike protein. Science 370:725–30
133. Tortorici MA, Veesler D. 2019. Structural insights into coronavirus entry. Adv. Virus Res. 105:93–116
134. Towler P, Staker B, Prasad SG, Menon S, Tang J, et al. 2004. ACE2 X-ray structures reveal a large
hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem. 279:17996–8007
135. Varsano N, Dadosh T, Kapishnikov S, Pereiro E, Shimoni E, et al. 2016. Development of correlative
cryo-soft X-ray tomography and stochastic reconstruction microscopy: a study of cholesterol crystal
early formation in cells. J. Am. Chem. Soc. 138:14931–40
136. Venkatagopalan P, Daskalova SM, Lopez LA, Dolezal KA, Hogue BG. 2015. Coronavirus envelope (E)
protein remains at the site of assembly. Virology 478:75–85
137. Walls AC, Park YJ, Tortorici MA,Wall A, McGuire AT, Veesler D. 2020. Structure, function, and anti-
genicity of the SARS-CoV-2 spike glycoprotein. Cell 181:281–92
138. Walls AC, Xiong X, Park YJ, Tortorici MA, Snijder J, et al. 2019. Unexpected receptor functional
mimicry elucidates activation of coronavirus fusion. Cell 176:1026–39.e15










































































139. Wan Y, Shang J, Graham R, Baric RS, Li F. 2020. Receptor recognition by the novel coronavirus from
Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 94:e00127-20
140. Wang C, Li W, Drabek D, Okba NMA, van Haperen R, et al. 2020. A human monoclonal antibody
blocking SARS-CoV-2 infection.Nat. Commun. 11:2251
141. Wang K, ChenW, Zhou Y-S, Lian J-Q, Zhang Z, et al. 2020. SARS-CoV-2 invades host cells via a novel
route: CD147-spike protein. Signal Transduct. Target. Ther. 5:283
142. Wang Q,Wu J,Wang H, Gao Y, Liu Q, et al. 2020. Structural basis for RNA replication by the SARS-
CoV-2 polymerase. Cell 182:417–28.e13
143. Wang Q, Zhang Y, Wu L, Niu S, Song C, et al. 2020. Structural and functional basis of SARS-CoV-2
entry by using human ACE2. Cell 181:894–904.e9
144. Deleted in proof
145. Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. 2020. Site-specific glycan analysis of the
SARS-CoV-2 spike. Science 369:330–33
146. Wells SA. 2020. Rigidity, normal modes and flexible motion of a SARS-CoV-2 (COVID-19) protease
structure. bioRxiv 986190. https://doi.org/10.1101/2020.03.10.986190
147. Wiener RS, Cao YX, Hinds A, Ramirez MI, Williams MC. 2007. Angiotensin converting enzyme 2 is
primarily epithelial and is developmentally regulated in the mouse lung. J. Cell Biochem. 101:1278–91
148. Wolff G, Limpens RWAL, Zevenhoven-Dobbe JC, Laugks U, Zheng S, et al. 2020. A molecular pore
spans the double membrane of the coronavirus replication organelle. Science 369:1395–98
149. Wong SK, Li W, Moore MJ, Choe H, Farzan M. 2004. A 193-amino acid fragment of the SARS coro-
navirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279:3197–201
150. Woo PCY, Lau SKP, Lam CSF, Tsang AKL, Hui S-W, et al. 2014. Discovery of a novel bottlenose
dolphin coronavirus reveals a distinct species of marine mammal coronavirus in gammacoronavirus.
J. Virol. 88:1318–31
151. Wrapp D, McLellan JS. 2020. The 3.1-Angstrom cryo-electron microscopy structure of the porcine
epidemic diarrhea virus spike protein in the prefusion conformation. J. Virol. 93:e00923-19
152. Wrapp D,Wang N, Corbett KS, Goldsmith JA, Hsieh CL, et al. 2020. Cryo-EM structure of the 2019-
nCoV spike in the prefusion conformation. Science 367:1260–63
153. Wu K, Li W, Peng G, Li F. 2009. Crystal structure of NL63 respiratory coronavirus receptor-binding
domain complexed with its human receptor. PNAS 106:19970–74
154. Wu Y, Wang F, Shen C, Peng W, Li D, et al. 2020. A noncompeting pair of human neutralizing anti-
bodies block COVID-19 virus binding to its receptor ACE2. Science 368:1274–78
155. Xiong X,QuK,Ciazynska KA,HosmilloM,Carter AP, et al. 2020. A thermostable, closed SARS-CoV-2
spike protein trimer.Nat. Struct. Mol. Biol. 27:934–41
156. Xu H, Zhong L, Deng J, Peng J, Dan H, et al. 2020. High expression of ACE2 receptor of 2019-nCoV
on the epithelial cells of oral mucosa. Int. J. Oral Sci. 12:8
157. Xue X, Yu H, Yang H, Xue F,Wu Z, et al. 2008. Structures of two coronavirus main proteases: implica-
tions for substrate binding and antiviral drug design. J. Virol. 82:2515–27
158. Yan B, Chu H, Yang D, Sze KH, Lai PM, et al. 2019. Characterization of the lipidomic profile of human
coronavirus-infected cells: implications for lipid metabolism remodeling upon coronavirus replication.
Viruses 11:73
159. Yan R, Zhang Y, Li Y, Xia L,Guo Y, Zhou Q. 2020. Structural basis for the recognition of SARS-CoV-2
by full-length human ACE2. Science 367:1444–48
160. Ye Y, Hogue BG. 2007. Role of the coronavirus E viroporin protein transmembrane domain in virus
assembly. J. Virol. 81:3597–607
161. Yin W, Mao C, Luan X, Shen D-D, Shen Q, et al. 2020. Structural basis for inhibition of the RNA-
dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 368:1499–504
162. Yip KM,FischerN,Paknia E,Chari A, StarkH. 2020.Atomic resolution protein structure determination
by cryo-EM.Nature 587(7832):157–61
163. Yu J,Qiao S,Guo R,Wang X. 2020. Cryo-EM structures of HKU2 and SADS-CoV spike glycoproteins
provide insights into coronavirus evolution.Nat. Commun. 11:3070
164. YuanM,WuNC,ZhuX,LeeCD,SoRTY, et al. 2020.A highly conserved cryptic epitope in the receptor











































































165. Yuan Y, Cao D, Zhang Y, Ma J, Qi J, et al. 2017. Cryo-EM structures of MERS-CoV and SARS-CoV
spike glycoproteins reveal the dynamic receptor binding domains.Nat. Commun. 8:15092
166. ZhangL,LinD,SunX,CurthU,DrostenC, et al. 2020.Crystal structure of SARS-CoV-2main protease
provides a basis for design of improved α-ketoamide inhibitors. Science 368:409–12
167. Zhang P. 2019. Advances in cryo-electron tomography and subtomogram averaging and classification.
Curr. Opin. Struct. Biol. 58:249–58
168. Zhang R, Wang K, Lv W, Yu W, Xie S, et al. 2014. The ORF4a protein of human coronavirus 229E
functions as a viroporin that regulates viral production. Biochim. Biophys. Acta Biomembr. 1838:1088–95
169. Zhang Y,Kutaleladze TG. 2020.Molecular structure analyses suggest strategies to therapeutically target
SARS-CoV-2.Nat. Commun. 11:2920
170. Zhou H, Liu LP, Fang M, Li YM, Zheng YW. 2020. A potential ex vivo infection model of hu-
man induced pluripotent stem cell-3D organoids beyond coronavirus disease 2019. Histol. Histopathol.
35(10):1077–82
171. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, et al. 2020. A pneumonia outbreak associated with a
new coronavirus of probable bat origin.Nature 579:270–73
172. Zhou T, Tsybovsky Y, Gorman J, Rapp M, Cerutti G, et al. 2020. Cryo-EM structures of SARS-CoV-
2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of
receptor-binding domains. Cell Host Microbe 28:867–79.e5
173. Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr., et al. 2015. Protease inhibitors targeting coron-
avirus and filovirus entry. Antivir. Res. 116:76–84
174. Zhou Y, Yang Y,Huang J, Jiang S,Du L. 2019. Advances inMERS-CoV vaccines and therapeutics based
on the receptor-binding domain. Viruses 11:60
175. Ziebuhr J, Siddell SG. 1999. Processing of the human coronavirus 229E replicase polyproteins by the
virus-encoded 3C-like proteinase: identification of proteolytic products and cleavage sites common to
pp1a and pp1ab. J. Virol. 73:177–85
176. Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, et al. 2020. SARS-CoV-2 receptor ACE2
is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets
across tissues. Cell 181:1016–35.e19















































































Review of COVID-19 Antibody Therapies
Jiahui Chen, Kaifu Gao, Rui Wang, Duc Duy Nguyen, and Guo-Wei Wei                 1
The Mechanosensory Transduction Machinery in Inner Ear Hair Cells
Wang Zheng and Jeffrey R. Holt                                                             31
Structure of Phycobilisomes
Sen-Fang Sui                                                                                  53
Biophysics of Chromatin Remodeling
Ilana M. Nodelman and Gregory D. Bowman                                               73
Structures and Functions of Chromatin Fibers
Ping Chen, Wei Li, and Guohong Li                                                         95
From Bench to Keyboard and Back Again: A Brief History of Lambda
Phage Modeling
Michael G. Cortes, Yiruo Lin, Lanying Zeng, and Gábor Balázsi                         117
Recent Developments in the Field of Intrinsically Disordered Proteins:
Intrinsic Disorder–Based Emergence in Cellular Biology in Light of
the Physiological and Pathological Liquid–Liquid Phase Transitions
Vladimir N. Uversky                                                                         135
Biophysics of Notch Signaling
David Sprinzak and Stephen C. Blacklow                                                  157
Bayesian Inference: The Comprehensive Approach to Analyzing
Single-Molecule Experiments
Colin D. Kinz-Thompson, Korak Kumar Ray, and Ruben L. Gonzalez Jr.               191
Learning to Model G-Quadruplexes: Current Methods and
Perspectives
Iker Ortiz de Luzuriaga, Xabier Lopez, and Adrià Gil                                    209
Analysis of Tandem Repeat Protein Folding Using
Nearest-Neighbor Models











































































BB50_FrontMatter ARjats.cls April 11, 2021 12:35
Biomolecular Modeling and Simulation: A Prospering
Multidisciplinary Field
Tamar Schlick, Stephanie Portillo-Ledesma, Christopher G. Myers,
Lauren Beljak, Justin Chen, Sami Dakhel, Daniel Darling, Sayak Ghosh,
Joseph Hall, Mikaeel Jan, Emily Liang, Sera Saju, Mackenzie Vohr,
Chris Wu, Yifan Xu, and Eva Xue                                                       267
Biomolecular Systems Engineering: Unlocking the Potential of
Engineered Allostery via the Lactose Repressor Topology
Thomas M. Groseclose, Ronald E. Rondon, Ashley N. Hersey, Prasaad T. Milner,
Dowan Kim, Fumin Zhang, Matthew J. Realff, and Corey J. Wilson                 303
Directed Evolution of Microbial Communities
Álvaro Sánchez, Jean C.C. Vila, Chang-Yu Chang, Juan Diaz-Colunga,
Sylvie Estrela, and María Rebolleda-Gomez                                             323
The Molecular Basis for Life in Extreme Environments
Nozomi Ando, Blanca Barquera, Douglas H. Bartlett, Eric Boyd,
Audrey A. Burnim, Amanda S. Byer, Daniel Colman, Richard E. Gillilan,
Martin Gruebele, George Makhatadze, Catherine A. Royer, Everett Shock,
A. Joshua Wand, and Maxwell B. Watkins                                              343
The Sliding Filament Theory Since Andrew Huxley: Multiscale and
Multidisciplinary Muscle Research
Joseph D. Powers, Sage A. Malingen, Michael Regnier, and Thomas L. Daniel          373
How Physical Interactions Shape Bacterial Biofilms
Berenike Maier                                                                               401
Cutting-Edge Single-Molecule Technologies Unveil New Mechanics
in Cellular Biochemistry
Souradeep Banerjee, Soham Chakraborty, Abhijit Sreepada, Devshuvam Banerji,
Shashwat Goyal, Yajushi Khurana, and Shubhasis Haldar                              419
Measuring Absolute Membrane Potential Across Space and Time
Julia R. Lazzari-Dean, Anneliese M.M. Gest, and Evan W. Miller                      447
Advancing Biophysics Using DNA Origami
Wouter Engelen and Hendrik Dietz                                                         469
The Contribution of Biophysics and Structural Biology to Current
Advances in COVID-19
Francisco J. Barrantes                                                                        493
Protein Reconstitution Inside Giant Unilamellar Vesicles
Thomas Litschel and Petra Schwille                                                         525
Structure and Mechanics of Dynein Motors
John T. Canty, Ruensern Tan, Emre Kusakci, Jonathan Fernandes,











































































BB50_FrontMatter ARjats.cls April 11, 2021 12:35
The Phasor Plot: A Universal Circle to Advance Fluorescence Lifetime
Analysis and Interpretation
Leonel Malacrida, Suman Ranjit, David M. Jameson, and Enrico Gratton              575
Molecular Force Measurement with Tension Sensors
Lisa S. Fischer, Srishti Rangarajan, Tanmay Sadhanasatish, and Carsten Grashoff      595
Indexes
Cumulative Index of Contributing Authors, Volumes 46–50                            617
Errata
An online log of corrections to Annual Review of Biophysics articles may be found at
http://www.annualreviews.org/errata/biophys
Contents vii
A
nn
u.
 R
ev
. B
io
ph
ys
. 2
02
1.
50
:4
93
-5
23
. D
ow
nl
oa
de
d 
fr
om
 w
w
w
.a
nn
ua
lr
ev
ie
w
s.
or
g
 A
cc
es
s 
pr
ov
id
ed
 b
y 
19
0.
10
5.
59
.1
62
 o
n 
05
/0
7/
21
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
